FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121079917> ?p ?o ?g. }

• W3121079917 abstract "Abstract Purpose To assess the prevalence of vitreomacular adhesion (VMA) in consecutive naïve eyes diagnosed with macular oedema (ME) secondary to retinal vein occlusion (RVO) and to longitudinally evaluate the incidence of vitreomacular interface changes over time and the influence on response to treatment. Design Retrospective cross‐sectional analysis and longitudinal cohort study conducted at two Italian tertiary referral centres. Methods A total of 295 eyes, treated with intravitreal ranibizumab and/or dexamethasone for ME secondary to RVO between June 2008 and May 2018, were enrolled in the study. 280 fellow eyes met the inclusion criteria and were included as control group. The vitreomacular interface status was evaluated by spectral domain optical coherence tomography (OCT) and graded according to the OCT‐based International Classification System developed by the International Vitreomacular Traction Study (IVTS) group. Results At baseline, VMA was present in 130 (44.07%) RVO eyes and 142 (50.7%) control eyes (no statistically significant difference was found; p = 0.455). Mean follow‐up (FU) was 35.98 months (min 6 – max 112). Throughout the FU, the incidence of spontaneous release of VMA (RVMA) in RVO eyes was significantly higher in comparison with that of the control group [59 (41.84%) RVO eyes versus 18 (12.33%) control eyes; p < 0.0001]. The number of injections in VMA+ eyes was significantly higher when compared with VMA− eyes. No significant difference was found between VMA+ and VMA− eyes regarding their mean best‐corrected visual acuity (BCVA) at baseline and at each annual time point (p = 0.2). Differences in central macular thickness (CMT) were significant only at the baseline evaluation (p = 0.0303). Conclusions Vitreomacular adhesion (VMA) was not found to be more prevalent in eyes with RVO compared to healthy fellow eyes, and RVO, in turn, did not result in a higher persistence of VMA over time. This suggests that VMA and RVO might be two independent retinal phenomena, with no mutual pathogenetic influence. Vitreomacular adhesion (VMA) might have an impact on the response to treatment, since it was found to result in a more intensive treatment regimen; however, it did not affect visual and anatomic outcomes. These results do not support vitrectomy or PVD induction in the prevention, nor the treatment, of RVO." @default.
• W3121079917 created "2021-01-18" @default.
• W3121079917 creator A5011699494 @default.
• W3121079917 creator A5014873875 @default.
• W3121079917 creator A5023505198 @default.
• W3121079917 creator A5024049616 @default.
• W3121079917 creator A5046481765 @default.
• W3121079917 creator A5068741066 @default.
• W3121079917 creator A5088612566 @default.
• W3121079917 date "2021-01-09" @default.
• W3121079917 modified "2023-10-17" @default.
• W3121079917 title "The prevalence of vitreomacular adhesion in eyes with macular oedema secondary to retinal vein occlusion selected for intravitreal injections" @default.
• W3121079917 cites W126729017 @default.
• W3121079917 cites W1481741390 @default.
• W3121079917 cites W1547355535 @default.
• W3121079917 cites W1967122471 @default.
• W3121079917 cites W1967505001 @default.
• W3121079917 cites W1975730266 @default.
• W3121079917 cites W1977355908 @default.
• W3121079917 cites W1978949856 @default.
• W3121079917 cites W1989218687 @default.
• W3121079917 cites W2014055461 @default.
• W3121079917 cites W2016138786 @default.
• W3121079917 cites W2017262248 @default.
• W3121079917 cites W2021149044 @default.
• W3121079917 cites W2021339592 @default.
• W3121079917 cites W2023343217 @default.
• W3121079917 cites W2024848735 @default.
• W3121079917 cites W2034956469 @default.
• W3121079917 cites W2042625705 @default.
• W3121079917 cites W2052943702 @default.
• W3121079917 cites W2063056873 @default.
• W3121079917 cites W2089952742 @default.
• W3121079917 cites W2092054885 @default.
• W3121079917 cites W2094360427 @default.
• W3121079917 cites W2100599719 @default.
• W3121079917 cites W2125419158 @default.
• W3121079917 cites W2317446018 @default.
• W3121079917 cites W2589103217 @default.
• W3121079917 cites W2592596405 @default.
• W3121079917 cites W2620887047 @default.
• W3121079917 cites W2622508885 @default.
• W3121079917 cites W2772005413 @default.
• W3121079917 cites W4243443641 @default.
• W3121079917 cites W561335032 @default.
• W3121079917 doi "https://doi.org/10.1111/aos.14746" @default.
• W3121079917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33421346" @default.
• W3121079917 hasPublicationYear "2021" @default.
• W3121079917 type Work @default.
• W3121079917 sameAs 3121079917 @default.
• W3121079917 citedByCount "0" @default.
• W3121079917 crossrefType "journal-article" @default.
• W3121079917 hasAuthorship W3121079917A5011699494 @default.
• W3121079917 hasAuthorship W3121079917A5014873875 @default.
• W3121079917 hasAuthorship W3121079917A5023505198 @default.
• W3121079917 hasAuthorship W3121079917A5024049616 @default.
• W3121079917 hasAuthorship W3121079917A5046481765 @default.
• W3121079917 hasAuthorship W3121079917A5068741066 @default.
• W3121079917 hasAuthorship W3121079917A5088612566 @default.
• W3121079917 hasBestOaLocation W31210799171 @default.
• W3121079917 hasConcept C118487528 @default.
• W3121079917 hasConcept C120665830 @default.
• W3121079917 hasConcept C121332964 @default.
• W3121079917 hasConcept C141071460 @default.
• W3121079917 hasConcept C2776268601 @default.
• W3121079917 hasConcept C2776694085 @default.
• W3121079917 hasConcept C2777802072 @default.
• W3121079917 hasConcept C2778257484 @default.
• W3121079917 hasConcept C2780347916 @default.
• W3121079917 hasConcept C2780827179 @default.
• W3121079917 hasConcept C2781100027 @default.
• W3121079917 hasConcept C2908732032 @default.
• W3121079917 hasConcept C61511704 @default.
• W3121079917 hasConcept C71924100 @default.
• W3121079917 hasConceptScore W3121079917C118487528 @default.
• W3121079917 hasConceptScore W3121079917C120665830 @default.
• W3121079917 hasConceptScore W3121079917C121332964 @default.
• W3121079917 hasConceptScore W3121079917C141071460 @default.
• W3121079917 hasConceptScore W3121079917C2776268601 @default.
• W3121079917 hasConceptScore W3121079917C2776694085 @default.
• W3121079917 hasConceptScore W3121079917C2777802072 @default.
• W3121079917 hasConceptScore W3121079917C2778257484 @default.
• W3121079917 hasConceptScore W3121079917C2780347916 @default.
• W3121079917 hasConceptScore W3121079917C2780827179 @default.
• W3121079917 hasConceptScore W3121079917C2781100027 @default.
• W3121079917 hasConceptScore W3121079917C2908732032 @default.
• W3121079917 hasConceptScore W3121079917C61511704 @default.
• W3121079917 hasConceptScore W3121079917C71924100 @default.
• W3121079917 hasIssue "7" @default.
• W3121079917 hasLocation W31210799171 @default.
• W3121079917 hasLocation W31210799172 @default.
• W3121079917 hasOpenAccess W3121079917 @default.
• W3121079917 hasPrimaryLocation W31210799171 @default.
• W3121079917 hasRelatedWork W1668980245 @default.
• W3121079917 hasRelatedWork W1972614420 @default.
• W3121079917 hasRelatedWork W1997095687 @default.
• W3121079917 hasRelatedWork W2022819203 @default.
• W3121079917 hasRelatedWork W2023340561 @default.
• W3121079917 hasRelatedWork W2605504011 @default.
• W3121079917 hasRelatedWork W2612234138 @default.

• next